The COVID-19 pandemic in the WHO African region: the first year (February 2020 to February 2021).


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
04 11 2021
Historique:
pubmed: 5 11 2021
medline: 8 1 2022
entrez: 4 11 2021
Statut: epublish

Résumé

The World Health Organization African region recorded its first laboratory-confirmed coronavirus disease-2019 (COVID-19) cases on 25 February 2020. Two months later, all the 47 countries of the region were affected. The first anniversary of the pandemic occurred in a changed context with the emergence of new variants of concern (VOC) and growing COVID-19 fatigue. This study describes the epidemiological trajectory of COVID-19 in the region, summarises public health and social measures (PHSM) implemented and discusses their impact on the pandemic trajectory. As of 24 February 2021, the African region accounted for 2.5% of cases and 2.9% of deaths reported globally. Of the 13 countries that submitted detailed line listing of cases, the proportion of cases with at least one co-morbid condition was estimated at 3.3% of all cases. Hypertension, diabetes and human immunodeficiency virus (HIV) infection were the most common comorbid conditions, accounting for 11.1%, 7.1% and 5.0% of cases with comorbidities, respectively. Overall, the case fatality ratio (CFR) in patients with comorbid conditions was higher than in patients without comorbid conditions: 5.5% vs. 1.0% (P < 0.0001). Countries started to implement lockdown measures in early March 2020. This contributed to slow the spread of the pandemic at the early stage while the gradual ease of lockdowns from 20 April 2020 resulted in an upsurge. The second wave of the pandemic, which started in November 2020, coincided with the emergence of the new variants of concern. Only 0.08% of the population from six countries received at least one dose of the COVID-19 vaccine. It is critical to not only learn from the past 12 months to improve the effectiveness of the current response but also to start preparing the health systems for subsequent waves of the current pandemic and future pandemics.

Identifiants

pubmed: 34732270
doi: 10.1017/S0950268821002429
pii: S0950268821002429
pmc: PMC8712926
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e263

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Références

Cas Lek Cesk. 1968 Aug 9;107(32):975-7
pubmed: 5679073
Science. 2021 Jan 1;371(6524):27-28
pubmed: 33384364
Lancet Microbe. 2020 May;1(1):e12
pubmed: 32835324
Lancet Glob Health. 2021 Jun;9(6):e773-e781
pubmed: 33711262
Int J Infect Dis. 2021 Jan;102:483-488
pubmed: 33010461
Lancet. 2021 Jan 30;397(10272):373
pubmed: 33484634
Lancet. 2021 Apr 3;397(10281):1265-1275
pubmed: 33773118
Pan Afr Med J. 2020 Nov 16;37(Suppl 1):37
pubmed: 33456661
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451367
Afr J Lab Med. 2020 May 14;9(1):1244
pubmed: 32537428
BMJ. 2021 Feb 17;372:n334
pubmed: 33597166
J Glob Health. 2020 Dec;10(2):020348
pubmed: 33110546
Lancet Glob Health. 2021 Jun;9(6):e724-e725
pubmed: 33711261
Lancet. 2021 May 22;397(10288):1885-1894
pubmed: 34022988
Public Health Pract (Oxf). 2020 Nov;1:100038
pubmed: 34173573
New Microbes New Infect. 2018 Sep 21;26:S10-S18
pubmed: 30402238
Biosecur Bioterror. 2013 Sep;11(3):163-9
pubmed: 24041192
Am J Trop Med Hyg. 2021 Mar 8;:
pubmed: 33684067
Health Secur. 2016 May-Jun;14(3):185-8
pubmed: 27314658
Lancet. 2020 Mar 14;395(10227):871-877
pubmed: 32087820

Auteurs

Benido Impouma (B)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.
Institute of Global Health, University of Geneva, Geneva, Switzerland.

Franck Mboussou (F)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Bridget Farham (B)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Caitlin M Wolfe (CM)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.
College of Public Health, University of South Florida, Tampa, Florida, USA.

Krys Johnson (K)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.
Department of Epidemiology and Biostatistics, Temple University, Philadelphia, Pennsylvania, USA.

Catherine Clary (C)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Richard Mihigo (R)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ngoy Nsenga (N)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ambrose Talisuna (A)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Zabulon Yoti (Z)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Antoine Flahault (A)

Institute of Global Health, University of Geneva, Geneva, Switzerland.

Olivia Keiser (O)

Institute of Global Health, University of Geneva, Geneva, Switzerland.

Abdou Salam Gueye (AS)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Joseph Cabore (J)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Matshidiso Moeti (M)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH